Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Single-Cell Analysis of Crohn's Disease Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF Therapy.

Martin JC, Chang C, Boschetti G, Ungaro R, Giri M, Grout JA, Gettler K, Chuang LS, Nayar S, Greenstein AJ, Dubinsky M, Walker L, Leader A, Fine JS, Whitehurst CE, Mbow ML, Kugathasan S, Denson LA, Hyams JS, Friedman JR, Desai PT, Ko HM, Laface I, Akturk G, Schadt EE, Salmon H, Gnjatic S, Rahman AH, Merad M, Cho JH, Kenigsberg E.

Cell. 2019 Sep 5;178(6):1493-1508.e20. doi: 10.1016/j.cell.2019.08.008. Epub 2019 Aug 29.

PMID:
31474370
2.

Retrospective analysis of model-based predictivity of human pharmacokinetics for anti-IL-36R monoclonal antibody MAB92 using a rat anti-mouse IL-36R monoclonal antibody and RNA expression data (FANTOM5).

Ahlberg J, Giragossian C, Li H, Myzithras M, Raymond E, Caviness G, Grimaldi C, Brown SE, Perez R, Yang D, Kroe-Barrett R, Joseph D, Pamulapati C, Coble K, Ruus P, Woska JR, Ganesan R, Hansel S, Mbow ML.

MAbs. 2019 Jul;11(5):956-964. doi: 10.1080/19420862.2019.1615345. Epub 2019 Jun 4.

3.

Inhibiting Interleukin 36 Receptor Signaling Reduces Fibrosis in Mice With Chronic Intestinal Inflammation.

Scheibe K, Kersten C, Schmied A, Vieth M, Primbs T, Carlé B, Knieling F, Claussen J, Klimowicz AC, Zheng J, Baum P, Meyer S, Schürmann S, Friedrich O, Waldner MJ, Rath T, Wirtz S, Kollias G, Ekici AB, Atreya R, Raymond EL, Mbow ML, Neurath MF, Neufert C.

Gastroenterology. 2019 Mar;156(4):1082-1097.e11. doi: 10.1053/j.gastro.2018.11.029. Epub 2018 Nov 16.

PMID:
30452921
4.

E3 Ubiquitin Ligase RNF125 Activates Interleukin-36 Receptor Signaling and Contributes to Its Turnover.

Saha SS, Caviness G, Yi G, Raymond EL, Mbow ML, Kao CC.

J Innate Immun. 2018;10(1):56-69. doi: 10.1159/000481210. Epub 2017 Nov 25.

5.

Generation and functional characterization of anti-human and anti-mouse IL-36R antagonist monoclonal antibodies.

Ganesan R, Raymond EL, Mennerich D, Woska JR Jr, Caviness G, Grimaldi C, Ahlberg J, Perez R, Roberts S, Yang D, Jerath K, Truncali K, Frego L, Sepulveda E, Gupta P, Brown SE, Howell MD, Canada KA, Kroe-Barrett R, Fine JS, Singh S, Mbow ML.

MAbs. 2017 Oct;9(7):1143-1154. doi: 10.1080/19420862.2017.1353853. Epub 2017 Jul 20.

6.

Structural and Functional Attributes of the Interleukin-36 Receptor.

Yi G, Ybe JA, Saha SS, Caviness G, Raymond E, Ganesan R, Mbow ML, Kao CC.

J Biol Chem. 2016 Aug 5;291(32):16597-609. doi: 10.1074/jbc.M116.723064. Epub 2016 Jun 15.

7.

Incorporation of Phosphonate into Benzonaphthyridine Toll-like Receptor 7 Agonists for Adsorption to Aluminum Hydroxide.

Cortez A, Li Y, Miller AT, Zhang X, Yue K, Maginnis J, Hampton J, Hall de S, Shapiro M, Nayak B, D'Oro U, Li C, Skibinski D, Mbow ML, Singh M, O'Hagan DT, Cooke MP, Valiante NM, Wu TY.

J Med Chem. 2016 Jun 23;59(12):5868-78. doi: 10.1021/acs.jmedchem.6b00489. Epub 2016 Jun 13.

PMID:
27270029
8.

Signal Transduction and Intracellular Trafficking by the Interleukin 36 Receptor.

Saha SS, Singh D, Raymond EL, Ganesan R, Caviness G, Grimaldi C, Woska JR Jr, Mennerich D, Brown SE, Mbow ML, Kao CC.

J Biol Chem. 2015 Sep 25;290(39):23997-4006. doi: 10.1074/jbc.M115.653378. Epub 2015 Aug 12.

9.

A new TLR2 agonist promotes cross-presentation by mouse and human antigen presenting cells.

Santone M, Aprea S, Wu TY, Cooke MP, Mbow ML, Valiante NM, Rush JS, Dougan S, Avalos A, Ploegh H, De Gregorio E, Buonsanti C, D'Oro U.

Hum Vaccin Immunother. 2015;11(8):2038-50. doi: 10.1080/21645515.2015.1027467.

10.

Rational design of small molecules as vaccine adjuvants.

Wu TY, Singh M, Miller AT, De Gregorio E, Doro F, D'Oro U, Skibinski DA, Mbow ML, Bufali S, Herman AE, Cortez A, Li Y, Nayak BP, Tritto E, Filippi CM, Otten GR, Brito LA, Monaci E, Li C, Aprea S, Valentini S, Calabrό S, Laera D, Brunelli B, Caproni E, Malyala P, Panchal RG, Warren TK, Bavari S, O'Hagan DT, Cooke MP, Valiante NM.

Sci Transl Med. 2014 Nov 19;6(263):263ra160. doi: 10.1126/scitranslmed.3009980.

11.

Loss of toll-like receptor 3 function improves glucose tolerance and reduces liver steatosis in obese mice.

Wu LH, Huang CC, Adhikarakunnathu S, San Mateo LR, Duffy KE, Rafferty P, Bugelski P, Raymond H, Deutsch H, Picha K, Ward CK, Alexoupolou L, Flavell RA, Mbow ML, Susulic VS.

Metabolism. 2012 Nov;61(11):1633-45. doi: 10.1016/j.metabol.2012.04.015. Epub 2012 May 17.

PMID:
22607770
12.

Development of an automated, high-throughput bactericidal assay that measures cellular respiration as a survival readout for Neisseria meningitidis.

Mak PA, Santos GF, Masterman KA, Janes J, Wacknov B, Vienken K, Giuliani M, Herman AE, Cooke M, Mbow ML, Donnelly J.

Clin Vaccine Immunol. 2011 Aug;18(8):1252-60. doi: 10.1128/CVI.05028-11. Epub 2011 Jun 29.

13.

Small molecule Toll-like receptor 7 agonists localize to the MHC class II loading compartment of human plasmacytoid dendritic cells.

Russo C, Cornella-Taracido I, Galli-Stampino L, Jain R, Harrington E, Isome Y, Tavarini S, Sammicheli C, Nuti S, Mbow ML, Valiante NM, Tallarico J, De Gregorio E, Soldaini E.

Blood. 2011 May 26;117(21):5683-91. doi: 10.1182/blood-2010-12-328138. Epub 2011 Apr 12.

PMID:
21487111
14.

Alum's adjuvant action: grease is the word.

Mbow ML, De Gregorio E, Ulmer JB.

Nat Med. 2011 Apr;17(4):415-6. doi: 10.1038/nm0411-415. No abstract available.

PMID:
21475229
15.

A point mutation in the amino terminus of TLR7 abolishes signaling without affecting ligand binding.

Iavarone C, Ramsauer K, Kubarenko AV, Debasitis JC, Leykin I, Weber AN, Siggs OM, Beutler B, Zhang P, Otten G, D'Oro U, Valiante NM, Mbow ML, Visintin A.

J Immunol. 2011 Apr 1;186(7):4213-22. doi: 10.4049/jimmunol.1003585. Epub 2011 Mar 7.

16.

New adjuvants for human vaccines.

Mbow ML, De Gregorio E, Valiante NM, Rappuoli R.

Curr Opin Immunol. 2010 Jun;22(3):411-6. doi: 10.1016/j.coi.2010.04.004. Epub 2010 May 11. Review.

PMID:
20466528
17.

Antibody affinity maturation and respiratory syncytial virus disease.

Shaw CA, Otten G, Wack A, Palmer GA, Mandl CW, Mbow ML, Valiante N, Dormitzer PR.

Nat Med. 2009 Jul;15(7):725; author reply 725-6. doi: 10.1038/nm0709-725a. No abstract available.

PMID:
19584854
18.

Long-term activation of TLR3 by poly(I:C) induces inflammation and impairs lung function in mice.

Stowell NC, Seideman J, Raymond HA, Smalley KA, Lamb RJ, Egenolf DD, Bugelski PJ, Murray LA, Marsters PA, Bunting RA, Flavell RA, Alexopoulou L, San Mateo LR, Griswold DE, Sarisky RT, Mbow ML, Das AM.

Respir Res. 2009 Jun 1;10:43. doi: 10.1186/1465-9921-10-43.

19.

Down modulation of human TLR3 function by a monoclonal antibody.

Duffy KE, Lamb RJ, San Mateo LR, Jordan JL, Canziani G, Brigham-Burke M, Korteweg J, Cunningham M, Beck HS, Carton J, Giles-Komar J, Duchala C, Sarisky RT, Mbow ML.

Cell Immunol. 2007 Aug;248(2):103-14. Epub 2007 Nov 28.

PMID:
18048020
20.
21.

Effects of single nucleotide polymorphisms on Toll-like receptor 3 activity and expression in cultured cells.

Ranjith-Kumar CT, Miller W, Sun J, Xiong J, Santos J, Yarbrough I, Lamb RJ, Mills J, Duffy KE, Hoose S, Cunningham M, Holzenburg A, Mbow ML, Sarisky RT, Kao CC.

J Biol Chem. 2007 Jun 15;282(24):17696-705. Epub 2007 Apr 13.

22.

Biochemical and functional analyses of the human Toll-like receptor 3 ectodomain.

Ranjith-Kumar CT, Miller W, Xiong J, Russell WK, Lamb R, Santos J, Duffy KE, Cleveland L, Park M, Bhardwaj K, Wu Z, Russell DH, Sarisky RT, Mbow ML, Kao CC.

J Biol Chem. 2007 Mar 9;282(10):7668-78. Epub 2007 Jan 5.

23.

A rapid and efficient method for generating anti-variable region monoclonal antibodies using type-1 interferons as immune modulators.

Staquet K, Fisher J, Lamb R, Bannish G, Duchala C, Mbow ML, Rycyzyn MA, Giles-Komar J.

Hum Antibodies. 2006;15(3):61-9.

PMID:
17065737
24.

Small molecule and biologic modulators of the immune response to hepatitis C virus.

Mbow ML, Eaton-Bassiri A, Glass WG, Del Vecchio AM, Sarisky RT.

Mini Rev Med Chem. 2006 May;6(5):527-31. Review.

PMID:
16719827
25.

A pathway analysis of poly(I:C)-induced global gene expression change in human peripheral blood mononuclear cells.

Huang CC, Duffy KE, San Mateo LR, Amegadzie BY, Sarisky RT, Mbow ML.

Physiol Genomics. 2006 Jul 12;26(2):125-33. Epub 2006 Mar 22.

26.

Structural and functional analyses of the human Toll-like receptor 3. Role of glycosylation.

Sun J, Duffy KE, Ranjith-Kumar CT, Xiong J, Lamb RJ, Santos J, Masarapu H, Cunningham M, Holzenburg A, Sarisky RT, Mbow ML, Kao C.

J Biol Chem. 2006 Apr 21;281(16):11144-51. Epub 2006 Feb 16.

27.

Modulating toll-like receptor signalling as a novel antiinfective approach.

Mbow ML, Sarisky RT.

Drug News Perspect. 2005 Apr;18(3):179-84. Review.

PMID:
15915219
28.

Exploiting toll-like receptors for designed multiple ligands.

Mbow ML, Sarisky RT.

Drug Discov Today. 2004 Dec 15;9(24):1038-9. No abstract available.

PMID:
15582790
29.

Toll-like receptor 9 can be expressed at the cell surface of distinct populations of tonsils and human peripheral blood mononuclear cells.

Eaton-Bassiri A, Dillon SB, Cunningham M, Rycyzyn MA, Mills J, Sarisky RT, Mbow ML.

Infect Immun. 2004 Dec;72(12):7202-11.

30.

Borrelia burgdorferi changes its surface antigenic expression in response to host immune responses.

Liang FT, Yan J, Mbow ML, Sviat SL, Gilmore RD, Mamula M, Fikrig E.

Infect Immun. 2004 Oct;72(10):5759-67.

31.

Immunization with Leishmania major exogenous antigens protects susceptible BALB/c mice against challenge infection with L. major.

Tonui WK, Mejia JS, Hochberg L, Mbow ML, Ryan JR, Chan AS, Martin SK, Titus RG.

Infect Immun. 2004 Oct;72(10):5654-61.

32.

What is disrupting IFN-alpha's antiviral activity?

Mbow ML, Sarisky RT.

Trends Biotechnol. 2004 Aug;22(8):395-9. Review.

PMID:
15283983
33.

Induction of dendritic cell maturation by IL-18.

Li J, Mbow ML, Sun L, Li L, Yang G, Griswold DE, Schantz A, Shealy DJ, Goletz TJ, Wan J, Peritt D.

Cell Immunol. 2004 Feb;227(2):103-8.

PMID:
15135292
34.
35.

Inability of outer-surface protein C (OspC)-primed mice to elicit a protective anamnestic immune response to a tick-transmitted challenge of Borrelia burgdorferi.

Gilmore RD Jr, Bacon RM, Carpio AM, Piesman J, Dolan MC, Mbow ML.

J Med Microbiol. 2003 Jul;52(Pt 7):551-6.

PMID:
12808075
36.

Borrelia burgdorferi-specific monoclonal antibodies derived from mice primed with Lyme disease spirochete-infected Ixodes scapularis ticks.

Mbow ML, Gilmore RD Jr, Stevenson B, Golde WT, Piesman J, Johnson BJ.

Hybrid Hybridomics. 2002 Jun;21(3):179-82.

PMID:
12165143
37.

Type 1 and type 2 responses to Leishmania major.

Rogers KA, DeKrey GK, Mbow ML, Gillespie RD, Brodskyn CI, Titus RG.

FEMS Microbiol Lett. 2002 Mar 19;209(1):1-7. Review.

38.

Analysis of Borrelia burgdorferi gene expression during life cycle phases of the tick vector Ixodes scapularis.

Gilmore RD Jr, Mbow ML, Stevenson B.

Microbes Infect. 2001 Aug;3(10):799-808.

PMID:
11580974
39.
40.

Surface exposure and protease insensitivity of Borrelia burgdorferi Erp (OspEF-related) lipoproteins.

El-Hage N, Babb K, Carroll JA, Lindstrom N, Fischer ER, Miller JC, Gilmore RD Jr, Mbow ML, Stevenson B.

Microbiology. 2001 Apr;147(Pt 4):821-30.

PMID:
11283278
42.

The immunomodulatory factors of bloodfeeding arthropod saliva.

Gillespie RD, Mbow ML, Titus RG.

Parasite Immunol. 2000 Jul;22(7):319-31. Review.

43.
44.
45.
46.

Vector competence of Ixodes scapularis and Ixodes ricinus (Acari: Ixodidae) for three genospecies of Borrelia burgdorferi.

Dolan MC, Piesman J, Mbow ML, Maupin GO, Péter O, Brossard M, Golde WT.

J Med Entomol. 1998 Jul;35(4):465-70.

PMID:
9701928
48.

Borrelia burgdorferi-pulsed dendritic cells induce a protective immune response against tick-transmitted spirochetes.

Mbow ML, Zeidner N, Panella N, Titus RG, Piesman J.

Infect Immun. 1997 Aug;65(8):3386-90.

Supplemental Content

Support Center